A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Study identifier:1839IL/0088

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Medical condition

Glioblastoma

Phase

Phase 2

Healthy volunteers

Study drug

Gefitinib

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2003

Primary Completion Date: -

Study Completion Date: 01 Mar 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Linköping, Sweden

Location

Research Site

Stockholm, Sweden

Location

Research Site

Umeå, Sweden

Arms	Assigned Interventions

Documents available

CSR-D7913L00088.pdf
Download
CSR-D7913L00088.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Sweden Medical Director

+46 8 553 229 89

Investigators

Principal Investigator

AstraZeneca Medical Science Director

AstraZeneca

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Documents available

CSR-D7913L00088.pdf

CSR-D7913L00088.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator